Novartis AG - ADR
NVS
Market Cap$240.74B
Close$
Earnings Call Q2 2024
July 18, 2024 - AI Summary
Novartis reported strong growth in Q2 2024, with sales up 11% in constant currency and core operating income up 19%. The company is confident in its ability to achieve its long-term targets of 5%+ sales growth through 2028 and a 40% core operating margin by 2027.
Key growth drivers for Novartis include Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio, Scemblix, and Fabhalta. These brands have shown steady growth and are expected to contribute significantly to the company's future revenue.
Entresto continues to perform well, with 28% growth in Q2 driven by demand in heart failure and hypertension. Novartis expects to exceed its $7 billion peak sales guidance for the medicine.
Exclusive for Stockcircle Pro members
Sign up
$122.74
6.1% upside
Current Fair Value
6.1% upsideUndervalued by 6.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $240.74 Billion |
|---|---|
| Enterprise Value | $262.17 Billion |
| Dividend Yield | $3.7395 (3.4%) |
| Earnings per Share | $7.84 |
| Beta | 0.34 |
| Outstanding Shares | 2,189,930,497 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.88 |
|---|---|
| PEG | 36.3 |
| Price to Sales | 5.51 |
| Price to Book Ratio | 6.09 |
| Enterprise Value to Revenue | 5.47 |
| Enterprise Value to EBIT | 22.15 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.7 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Novartis AG
CEO: Vasant Narasimhan Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...